<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688828</url>
  </required_header>
  <id_info>
    <org_study_id>BoulardiitoHp2018</org_study_id>
    <nct_id>NCT03688828</nct_id>
  </id_info>
  <brief_title>Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori</brief_title>
  <official_title>The Evaluation of Saccharomyces Boulardii Sachets Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori: a Prospective, Multi-Center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiaogan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiaogan First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Aerospace Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The third people's Hospital of Hubei Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anlu Puai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The eradication rate of standard quadruple therapy has become less successful due to low&#xD;
      compliance and high resistance to the antibiotics. Therefore, it is necessary to develop new&#xD;
      treatment strategies that increase the eradication rate and reduce adverse effects. The aims&#xD;
      of this prospective study is to investigate the efficacy of Saccharomyces Boulardii sachets&#xD;
      for eradication of Hp, compared with standard quadruple therap.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In China, the first-line therapy to treat Helicobacter pylori (Hp) consists of a&#xD;
      bismuth-based proton pump inhibitor (PPI) and two antibiotics for 14 days. But, eradication&#xD;
      has become less successful due to low compliance and high resistance to the antibiotics.&#xD;
      Therefore, it is necessary to develop new treatment strategies that increase the eradication&#xD;
      rate and reduce adverse effects. Several studies previously suggested that probiotics could&#xD;
      be effective for improving Hp eradication rate or reducing adverse events with PPI-based&#xD;
      triple therapy. But, their effect for eradication of Hp is not yet conclusive. And the&#xD;
      experiments now available about efficacy of Saccharomyces Boulardii were mainly combined with&#xD;
      triple therapy. The aims of this prospective study is to investigate the efficacy of&#xD;
      Saccharomyces Boulardii sachets for eradication of Hp, compared with standard quadruple&#xD;
      therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2018</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">June 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori eradication</measure>
    <time_frame>6 weeks after treatment initiation</time_frame>
    <description>to investigate the efficacy of Saccharomyces Boulardii sachets for eradication of Hp, compared with standard quadruple therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>2 weeks and 4-12 weeks after treatment initiation</time_frame>
    <description>to investigate the efficacy of Saccharomyces Boulardii sachets for reduction of incidence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin + Bismuth potassium citrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadruple Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole + Amoxicillin + Clarithromycin + Bismuth potassium citrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saccharomyces boulardii</intervention_name>
    <description>500mg bid</description>
    <arm_group_label>Probiotics</arm_group_label>
    <other_name>Brad's yeast powder;Biocodex, Paris, France</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>20mg bid</description>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_label>Quadruple Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>1.0g bid</description>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_label>Quadruple Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>0.5g bid</description>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_label>Quadruple Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth potassium citrate</intervention_name>
    <description>0.22g bid</description>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_label>Quadruple Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Helicobacter pylori infected patients&#xD;
&#xD;
          -  13C DOB&gt;8&#xD;
&#xD;
          -  age 22~65&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior Hp eradication therapy including amoxicillin and clarithromycin&#xD;
&#xD;
          -  previous gastric resection&#xD;
&#xD;
          -  allergic to the drugs used in this study&#xD;
&#xD;
          -  previous use of proton pump inhibitors, bismuth, H2 receptor antagonist or&#xD;
             antibiotics, probiotics within 4 weeks of the study&#xD;
&#xD;
          -  Patients who were pregnant or lactating&#xD;
&#xD;
          -  Patients taking NSAIDs, alcoholic or with other serious disease (e.g. hepatopathy,&#xD;
             heart disease, nephropathy，diabete mellitus, hypertension…) effect the evaluation of&#xD;
             this study&#xD;
&#xD;
          -  Can't express the complaint correctly&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bin Cheng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuchong Zhao, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical School, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Song MJ, Park DI, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010 Jun;15(3):206-13. doi: 10.1111/j.1523-5378.2010.00751.x.</citation>
    <PMID>20557362</PMID>
  </reference>
  <reference>
    <citation>Zojaji H, Ghobakhlou M, Rajabalinia H, Ataei E, Jahani Sherafat S, Moghimi-Dehkordi B, Bahreiny R. The efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of H.pylori: a randomized controlled trial. Gastroenterol Hepatol Bed Bench. 2013;6(Suppl 1):S99-S104.</citation>
    <PMID>24834296</PMID>
  </reference>
  <reference>
    <citation>Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010 Nov;32(9):1069-79. doi: 10.1111/j.1365-2036.2010.04457.x. Epub 2010 Sep 16. Erratum in: Aliment Pharmacol Ther. 2010 Dec;32(11-12):1408.</citation>
    <PMID>21039671</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Bin Cheng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Saccharomyces Boulardii</keyword>
  <keyword>Standard Quadruple Therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

